Five Clinical Trial Hits Of 2023

The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.

Sanofi and Regeneron Pharmaceuticals, Inc. are now well positioned to add a new blockbuster-sized indication to the labelling for their behemoth anti-inflammatory Dupixent (dupilumab), namely chronic obstructive pulmonary disease (COPD), following successful readouts for two identical Phase III trials this year.

The first of these, BOREAS, in March confounded skepticism surrounding the usefulness of biologics in this challenging respiratory condition in...